gdc
PSSGuide_2021
Multiple Myeloma

Drugs for Drugs for Multiple Myeloma

Find financial assistance programs available for multiple myeloma drugs.

Abecma (idecabtagene vicleucel)

Drug company: Bristol Myers Squibb/Bluebird Bio
888-805-4555

Abecma is a BCMA-directed genetically modified autologous T-cell therapy used for the treatment of adults with relapsed or refractory multiple myeloma after 4 or more previous lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Bristol Myers Squibb, through Cell Therapy 360, offers 2 financial assistance programs to patients using Abecma:

Cell Therapy 360 Copay Program

Eligible patients who have private or commercial insurance may receive financial benefits of up to $10,000 in out-of-pocket costs for Abecma through this program.

Cell Therapy 360 Patient Assistance Program

Eligible patients who are uninsured or underinsured, and whose household income is no more than 600% of the federal poverty level, may receive Abecma through this program.

Blenrep (belantamab mafodotin-blmf) Injection

Drug company: GlaxoSmithKline
844-447-5662

Blenrep is a BCMA-directed antibody and microtubule inhibitor conjugate used for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug.

GSK Oncology offers 2 financial assistance programs for patients who have been prescribed Blenrep:

Together with GSK Oncology Commercial Co-pay Program

Eligible patients who have private insurance can pay as little as $0 for Blenrep through this program, with a maximum benefit of $26,000 annually.

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Blenrep for free through this program. Qualified patients must have a maximum monthly household gross income of $5,366.67 for individuals; $7,258.33 for a family of 2; $9,150.00 for a family of 3; $11,041.67 for a family of 4; and $1,891.67 for each additional person.

Darzalex (daratumumab) Intravenous Injection

Drug company: Janssen Biotech
844-553-2792

Darzalex is a human anti-CD38 monoclonal antibody used, in combination with Revlimid and dexamethasone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant, and in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy; in combination with Velcade, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem-cell transplant; and in combination with Velcade, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem-cell transplant. Darzalex is also used, alone or in combination with Kyprolis and dexamethasone, or with Velcade and dexamethasone, for the treatment of multiple myeloma in patients who received at least 1 previous therapy; or with Pomalyst and dexamethasone for patients who received at least 2 previous therapies, including Revlimid and a proteasome inhibitor (PI); or as monotherapy in patients who received at least 3 previous therapies, including a PI and an immunomodulatory drug (IMiD), or who are double-refractory to a PI and an IMiD.

Janssen Biotech offers 3 financial assistance programs for patients using Darzalex:

Janssen CarePath Savings Program

With this program, privately insured patients will pay just $5 for the first 8 infusions of Darzalex, and $10 for each additional infusion, with a $20,000 maximum annual benefit.

Johnson & Johnson Patient Assistance Foundation

This program provides Darzalex free of charge for up to 12 months to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Janssen Compass

844-NAV-1234

Janssen Compass offers free, personalized support to patients who are prescribed a cancer drug from Janssen. Connect one-on-one with your dedicated Care Navigator (an experienced oncology nurse), who can help you find financial assistance and provide educational treatment support based on what you tell us you need most.

Darzalex Faspro (daratumumab + hyaluronidase-fihj) Subcutaneous Injection

Drug company: Janssen Biotech
844-553-2792

Darzalex Faspro is a combination of daratumumab, an anti- CD38 monoclonal antibody, and hyaluronidase, an endoglycosidase, that is used, in combination with Velcade, melphalan, and prednisone, for the treatment of newly diagnosed adults with multiple myeloma who are ineligible for autologous stem-cell transplant; in combination with Revlimid and dexamethasone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant, and in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy. Darzalex Faspro is also used, in combination with Velcade and dexamethasone, in patients who have received at least 1 previous therapy; and as monotherapy, in patients who have received at least 3 previous lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or who are double-refractory to a PI and an IMiD.

Janssen Biotech offers 3 financial assistance programs for patients who have been prescribed Darzalex Faspro:

Janssen CarePath Savings Program

Eligible patients who have private insurance will pay just $5 for each infusion of Darzalex Faspro, with a $20,000 maximum program benefit each calendar year.

Johnson & Johnson Patient Assistance Foundation

This program provides Darzalex Faspro free of charge for up to 12 months to patients who are uninsured or underinsured, and whose annual household income is less than $51,040 for 1 person; $68,960 for 2 people; $86,880 for 3 people; $104,800 for 4 people; and $122,720 for 5 people.

Janssen Compass

844-NAV-1234

Janssen Compass offers free, personalized support to patients who are prescribed a cancer drug from Janssen. Connect one-on-one with your dedicated Care Navigator (an experienced oncology nurse), who can help you find financial assistance and provide educational treatment support based on what you tell us you need most.

Empliciti (elotuzumab)

Drug company: Bristol Myers Squibb
800-861-0048

Empliciti is a SLAMF7-directed immunostimulatory antibody used, in combination with Revlimid and dexamethasone, for the treatment of patients with multiple myeloma, after 1 to 3 other therapies. Empliciti is also used, in combination with Pomalyst and dexamethasone, for adults with multiple myeloma after 2 previous therapies, including Revlimid and a proteasome inhibitor.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Empliciti:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Empliciti. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Empliciti may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Evomela (melphalan) for Injection

Drug company: Acrotech Biopharma
888-537-8277

Evomela is an alkylating drug used as a high-dose conditioning treatment before hematopoietic stem-cell transplant in patients with multiple myeloma. Evomela is also used as a palliative treatment for patients with multiple myeloma for whom oral therapy is not appropriate.

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients receiving Evomela:

STAR Co-pay Assistance

Eligible, privately insured patients will pay $0 out of pocket for the first injection of Evomela and then $25 for each subsequent injection, with a benefit of up to $10,000 per calendar year.

STAR Patient Assistance Program

This program provides Evomela free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Farydak (panobinostat) Capsules

Drug company: Secura Bio
844-973-2872

Farydak is a histone deacetylase inhibitor used, in combination with Velcade and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous treatment regimens that include Velcade and an immunomodulatory drug.

Secura Care provides 3 financial assistance programs for patients who have been prescribed Farydak:

Secura Care Copay/Coinsurance Assistance Program

Eligible patients would pay only $5. This program will provide up to $25,000 annually in copay assistance for patients receiving Farydak.

Secura Care Patient Assistance Program

Eligible patients who are underinsured or uninsured can receive Farydak at no cost through this program.

Secura Care Quickstart Program

Through this program, eligible patients who are experiencing a delay in drug coverage can receive Farydak at no cost.

Kyprolis (carfilzomib) Injection

Drug company: Amgen
888-427-7478

Kyprolis is a proteasome inhibitor used for the treatment of patients with relapsed or refractory multiple myeloma, as a single agent or in combination with dexamethasone or with Revlimid plus dexamethasone, after 1 to 3 therapies.

Amgen offers 3 financial assistance programs for patients using Kyprolis:

Amgen FIRST STEP Program

For privately insured patients whose insurance covers Kyprolis, this program ensures a patient copay of $0 for the first dose, and $5 for each dose thereafter, with a maximum benefit of $20,000 per patient per calendar year.

Amgen Assist 360

Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for the medication.

Amgen Safety Net Foundation

Qualified, uninsured patients can receive Kyprolis for free through Amgen’s nonprofit program, the Safety Net Foundation.

Mozobil (plerixafor) Injection

Drug company: Sanofi Aventis
888-847-4877

Mozobil is a hematopoietic stem-cells mobilizer used, in combination with granulocyte colony-stimulating factor, for the treatment of patients with multiple myeloma after autologous stem-cell transplant.

Sanofi Aventis, through Sano Cares North America, offers 1 financial assistance program to patients using Mozobil:

Sanofi Patient Assistance Connection

This program provides Mozobil at no cost to patients who have no insurance coverage or their insurance does not cover the cost of Mozobil, and they meet program eligibility requirements, and have an annual household income of 400% or less of the current federal poverty level. Patients with Medicaid must provide documentation of Medicaid denial before being assessed for patient assistance eligibility. Patients enrolled in Medicare Part D must meet certain financial criteria.

Ninlaro (ixazomib) Capsules

Drug company: Takeda Oncology
844-617-6468

Ninlaro is a proteasome inhibitor used, in combination with Revlimid and dexamethasone, for the treatment of patients with multiple myeloma.

Takeda Oncology offers 2 financial assistance programs for patients using Ninlaro:

Takeda Oncology Co-Pay Assistance Program

Patients with private insurance may pay as little as $10 per monthly prescription of Ninlaro, with a maximum benefit value of $25,000 annually.

Takeda Oncology Patient Assistance Program

Patients who do not have insurance may be eligible to receive their medication through this program at no cost. Patients must meet certain clinical, financial, and insurance coverage criteria.

Pepaxto (melphalan flufenamide) Injection

Drug company: Oncopeptides AB
844-300-6626

Pepaxto is a first-in-class alkylating drug approved for the treatment, in combination with dexamethasone, of adults with relapsed or refractory multiple myeloma who have received 4 or more previous lines of therapy and whose cancer is refractory to 1 or more proteasome inhibitors, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.

Celgene Patient Support offers 1 financial assistance programs for patients using Pomalyst:

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Eligible patients who are uninsured or underinsured may receive Pepaxto at no cost through this program. Some restrictions apply at no cost through this program. Some restrictions apply.
NOTE: On October 22, 2021, Oncopeptides announced that it voluntarily withdrew the accelerated indication for Pepaxto in the United States, after updated results from the phase 3 clinical trials; therefore, no new patient should begin to take Pepaxto. However, for patients who are currently using this drug, for a limited time, Oncopeptides will let qualified patients access Pepaxto free of charge through the Patient Assistance Program. Existing patients may access the application to continue receiving Pepaxto at www.pepaxtohcp.com/docs/Oncopeptides_ON_COURSE_Enrollment_Form.pdf.

Pomalyst (pomalidomide) Capsules

Drug company: Bristol Myers Squibb
800-861-0048

Pomalyst is a thalidomide analog used, in combination with dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies. Pomalyst is also used, in combination with Empliciti and dexamethasone, after previous therapies, for patients with multiple myeloma.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Pomalyst:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Pomalyst. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Pomalyst, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Revlimid (lenalidomide) Capsules

Drug company: Bristol Myers Squibb
800-861-0048

Revlimid is a thalidomide analog used for the treatment of patients with multiple myeloma, in combination with dexamethasone, and as maintenance therapy after autologous hematopoietic stem-cell transplant.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Revlimid. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Revlimid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Sarclisa (isatuximab-irfc) Injection

Drug company: Sanofi Genzyme
833-930-2273

Sarclisa is a CD38-directed cytolytic antibody used, in combination with Pomalyst and dexamethasone, for the treatment of adults with multiple myeloma who have received at least 2 therapies that include Revlimid and a proteasome inhibitor. Sarclisa is also used, in combination with Kyprolis and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy.

Sanofi Genzyme offer 2 financial assistance programs for patients who have been prescribed Sarclisa:

CareASSIST Copay Program

Eligible patients who have private insurance may pay as little as $0 for Sarclisa, with a maximum benefit limit of $25,000 annually. This program has no income requirements for participation.

CareASSIST Patient Assistance Program

Eligible patients who are uninsured or underinsured and who have an annual household income of less than $100,000, or 500% of the federal poverty level, may be able to receive Sarclisa for free.

Thalomid (thalidomide)

Drug company: Bristol Myers Squibb
800-861-0048

Thalomid is a thalidomide used, in combination with dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Thalomid:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Thalomid. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Thalomid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Velcade (bortezomib) for Injection

Drug company: Takeda Oncology
844-617-6468

Velcade is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Velcade is also used, in combination with Darzalex and dexamethasone, or with Farydak and dexamethasone, for patients with multiple myeloma.

Takeda Oncology offers 2 financial assistance programs for patients using Velcade:

Velcade Reimbursement Assistance Program

For patients with Medicare, Medicaid, or private insurance, this program will help find supplemental coverage if needed and provide assistance with copays.

Velcade Patient Assistance Program

Patients without insurance coverage may qualify to receive their medication free of charge through this program. Patient eligibility is based on household income, treatment setting, and medically appropriate need.

Xpovio (selinexor)

Drug company: Karyopharm Therapeutics
877-527-9493

Xpovio is a nuclear export inhibitor used, in combination with dexamethasone, for the treatment of relapsed or refractory multiple myeloma after at least 4 previous therapies in adults whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and to an anti- CD38 monoclonal antibody.

Karyopharm Therapeutics offers 3 financial assistance programs for patients who have been prescribed Xpovio:

Xpovio Co-pay Card Program

Eligible patients with private insurance may pay just $5 copay per prescription of Xpovio, with a maximum of $8,000 per 30-day prescription and up to a total benefit of $25,000 per calendar year.

Xpovio QuickStart

Patients receiving their first prescription of Xpovio, who cannot ascertain coverage or verification of coverage within 5 business days may be eligible for this program.

Xpovio Patient Assistance Program

This program provides Xpovio free of charge to uninsured patients who meet specific financial criteria.

Table. Drugs Prescribed for Multiple Myeloma

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Abecma (idecabtagene vicleucel)
  • Drug company
  • Bristol Myers Squibb/Bluebird Bio
  • Indication
  • Treatment of adults with relapsed or refractory multiple myeloma after 4 or more previous lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
  • Patient support services
  • Cell Therapy 360 Copay Program
    888-805-4555

    Cell Therapy 360 Patient Assistance Program
    888-805-4555

    Drug name (generic name)
  • Blenrep (belantamab mafodotinblmf) Injection
  • Drug company
  • GSK Oncology
  • Indication
  • Treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug
  • Patient support services
  • Together with GSK Oncology Commercial Co-pay Program
    844-447-5662

    Patient Assistance Program
    844-447-5662

    Drug name (generic name)
  • Darzalex (daratumumab) Intravenous Injection
  • Drug company
  • Janssen Biotech
  • Indication
  • Treatment of multiple myeloma, in combination with lenalidomide and dexamethasone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant, and in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy

    Treatment of multiple myeloma, in combination with bortezomib, melphalan, and prednisone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant

    Treatment of multiple myeloma, in combination with bortezomib, thalidomide, and dexamethasone, in newly diagnosed patients who are eligible for autologous stem-cell transplant

    Treatment of multiple myeloma, in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, after 1 therapy

    Treatment of multiple myeloma, in combination with pomalidomide and dexamethasone, after 2 therapies

    Treatment of multiple myeloma, as monotherapy, after 3 therapies
  • Patient support services
  • Janssen CarePath Savings Program
    844-553-2792

    Johnson & Johnson Patient Assistance Foundation
    800-652-6227

    Janssen Compass
    844-NAV-1234

    Drug name (generic name)
  • Darzalex Faspro (daratumumab + hyaluronidase-fihj) Subcutaneous Injection
  • Drug company
  • Janssen Biotech
  • Indication
  • First-line treatment, in combination with Velcade, melphalan, and prednisone, of patients who are ineligible for a transplant

    Treatment, in combination with Revlimid and dexamethasone, of newly diagnosed patients who are ineligible for a transplant, or patients with relapsed or refractory multiple myeloma who have received at least 1 therapy

    Treatment, in combination with Velcade and dexamethasone, of patients who have received at least 1 previous therapy

    As monotherapy for patients who have received at least 3 previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who are double-refractory to a proteasome inhibitor and an immunomodulatory drug
  • Patient support services
  • Janssen CarePath Savings Program
    844-553-2792

    Johnson & Johnson Patient Assistance Foundation
    800-652-6227

    Janssen Compass
    844-NAV-1234

    Drug name (generic name)
  • Empliciti (elotuzumab)
  • Drug company
  • Bristol Myers Squibb
  • Indication
  • Multiple myeloma, in combination with Revlimid and dexamethasone, after 1 to 3 therapies

    Multiple myeloma, in combination with Pomalyst and dexamethasone, after 2 therapies, including Revlimid and a proteasome inhibitor
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003

    Drug name (generic name)
  • Evomela (melphalan) for Injection
  • Drug company
  • Acrotech Biopharma
  • Indication
  • Conditioning treatment before stem-cell transplant in patients with multiple myeloma

    Palliative treatment for patients with multiple myeloma
  • Patient support services
  • STAR Co-pay Assistance
    888-537-8277

    STAR Patient Assistance Program
    888-537-8277


    Drug name (generic name)
  • Kyprolis (carfilzomib) Injection
  • Drug company
  • Amgen
  • Indication
  • Relapsed or refractory multiple myeloma, as a single agent or in combination with dexamethasone or with Revlimid plus dexamethasone
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Assist 360
    888-427-7478

    Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Mozobil (plerixafor)
  • Drug company
  • Sanofi Genzyme
  • Indication
  • Treatment of multiple myeloma, in combination with granulocyte colony-stimulating factor, after autologous stem-cell transplant
  • Patient support services
  • Sanofi Patient Assistance Connection
    888-847-4877


    Drug name (generic name)
  • Pepaxto (melphalan flufenamide) Injection
  • Drug company
  • Oncopeptides AB
  • Indication
  • Treatment, in combination with dexamethasone, of adults with relapsed or refractory multiple myeloma who have received 4 or more previous lines of therapy and whose cancer is refractory to 1 or more proteasome inhibitors, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody
  • Patient support services
  • Patient Assistance Program
    844-300-6626



    Drug name (generic name)
  • Sarclisa (isatuximab-irfc) Injection
  • Drug company
  • Sanofi Genzyme
  • Indication
  • Treatment, in combination with Pomalyst and dexamethasone, of adults with multiple myeloma who have received at least 2 therapies that include Revlimid and a proteasome inhibitor
    Treatment, in combination with Kyprolis and dexamethasone, of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy
  • Patient support services
  • CareASSIST Copay Program
    833-930-2273

    CareASSIST Patient Assistance Program
    833-930-2273



    Drug name (generic name)
  • Xpovio (selinexor)
  • Drug company
  • Karyopharm Therapeutics
  • Indication
  • Treatment of relapsed or refractory multiple myeloma, after at least 4 previous therapies and disease refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
    Treatment, in combination with Velcade and dexamethasone, for adults with multiple myeloma who have received at least 1 previous therapy
  • Patient support services
  • Xpovio Co-pay Card Program
    877-527-9493

    Xpovio QuickStart
    877-527-9493

    Xpovio Patient Assistance Program
    877-527-9493

Share this:

Last modified: April 1, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests